Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS).

IF 1.7 Q4 RESPIRATORY SYSTEM
Pneumologie Pub Date : 2025-06-01 Epub Date: 2023-08-25 DOI:10.1055/a-2102-8128
Katrin Milger, Stephanie Korn, Claudia Feder, Jan Fuge, Andreas Mühle, Wolfgang Schütte, Dirk Skowasch, Hartmut Timmermann, Hendrik Suhling
{"title":"Criteria for evaluation of response to biologics in severe asthma - the Biologics Asthma Response Score (BARS).","authors":"Katrin Milger, Stephanie Korn, Claudia Feder, Jan Fuge, Andreas Mühle, Wolfgang Schütte, Dirk Skowasch, Hartmut Timmermann, Hendrik Suhling","doi":"10.1055/a-2102-8128","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong> The introduction of monoclonal antibodies (biologics) has revolutionized the therapy of severe asthma. Even though there is a response in the majority of patients, the degree of response varies. To date criteria for assessment of response to biologics are not consistently defined.</p><p><strong>Aim: </strong> To define criteria for evaluation of response to biologics that are precise, simple and suitable for daily use in order to guide decision-making regarding continuation, switching or stopping of biological therapy.</p><p><strong>Methods: </strong> 8 physicians with large experience in this indication, supported by a data-scientist, developed a consensus on criteria to evaluate response to biologics in patients with severe asthma.</p><p><strong>Result: </strong> We developed a combined score based on current literature, own experience and practicability. It uses the main criteria exacerbations, oral corticosteroid (OCS) therapy and asthma control (asthma control test, ACT). We defined thresholds for \"good response\", \"response\" and \"insufficient response\" rated with a score of \"2\", \"1\" and \"0\" respectively: annual exacerbations (\"0 or reduction ≥ 75 %\", \"reduction 50-74 %\", \"reductio < 50 %\"), daily OCS dose (\"stopping or reduction ≥ 75 %\", \"reduction 50-74 %\", \"reduction < 50 %\"), asthma control (\"ACT increase ≥ 6 or ≥ 3 with result ≥ 20\", \"ACT increase 3-5 with result < 20\", \"ACT increase < 3\"). Additional individual criteria like lung function and comorbidities may be important for evaluation of response. We propose 3, 6 and 12 months timepoint for assessment of tolerability and response. Using the combined score, we developed a scheme to guide the decision whether switching the biologic should be considered.</p><p><strong>Conclusion: </strong> The Biologic Asthma Response Score (BARS) serves as objective and simple tool to evaluate response to biologic therapy using the three main criteria exacerbations, OCS use and asthma control. A validation of the score was initiated.</p>","PeriodicalId":20197,"journal":{"name":"Pneumologie","volume":" ","pages":"439-451"},"PeriodicalIF":1.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12202053/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pneumologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2102-8128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/25 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background:  The introduction of monoclonal antibodies (biologics) has revolutionized the therapy of severe asthma. Even though there is a response in the majority of patients, the degree of response varies. To date criteria for assessment of response to biologics are not consistently defined.

Aim:  To define criteria for evaluation of response to biologics that are precise, simple and suitable for daily use in order to guide decision-making regarding continuation, switching or stopping of biological therapy.

Methods:  8 physicians with large experience in this indication, supported by a data-scientist, developed a consensus on criteria to evaluate response to biologics in patients with severe asthma.

Result:  We developed a combined score based on current literature, own experience and practicability. It uses the main criteria exacerbations, oral corticosteroid (OCS) therapy and asthma control (asthma control test, ACT). We defined thresholds for "good response", "response" and "insufficient response" rated with a score of "2", "1" and "0" respectively: annual exacerbations ("0 or reduction ≥ 75 %", "reduction 50-74 %", "reductio < 50 %"), daily OCS dose ("stopping or reduction ≥ 75 %", "reduction 50-74 %", "reduction < 50 %"), asthma control ("ACT increase ≥ 6 or ≥ 3 with result ≥ 20", "ACT increase 3-5 with result < 20", "ACT increase < 3"). Additional individual criteria like lung function and comorbidities may be important for evaluation of response. We propose 3, 6 and 12 months timepoint for assessment of tolerability and response. Using the combined score, we developed a scheme to guide the decision whether switching the biologic should be considered.

Conclusion:  The Biologic Asthma Response Score (BARS) serves as objective and simple tool to evaluate response to biologic therapy using the three main criteria exacerbations, OCS use and asthma control. A validation of the score was initiated.

重度哮喘患者对生物制剂反应的评价标准——生物制剂哮喘反应评分(BARS)。
背景:单克隆抗体(生物制剂)的引入使重症哮喘的治疗发生了革命性的变化。尽管大多数患者都有反应,但反应的程度各不相同。迄今为止,评估对生物制剂反应的标准还没有一致的定义。目的:确定准确、简单、适合日常使用的生物制剂反应评价标准,以指导继续、切换或停止生物治疗的决策。方法:在一名数据科学家的支持下,8名在该适应症方面经验丰富的医生就评估严重哮喘患者对生物制剂反应的标准达成共识。结果:我们根据现有文献、自身经验和实用性制定了一个综合评分。它使用的主要标准是急性加重、口服皮质类固醇(OCS)治疗和哮喘控制(哮喘控制试验,ACT)。我们定义了“良好反应”、“反应”和“反应不足”的阈值,评分分别为“2”、“1”和“0”:年加重(“0或减轻≥75%”、“减轻50- 74%”、“减轻”)。结论:哮喘生物反应评分(BARS)是一种客观、简单的工具,可以使用加重、OCS使用和哮喘控制三个主要标准来评估对生物治疗的反应。开始对分数进行验证。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pneumologie
Pneumologie RESPIRATORY SYSTEM-
CiteScore
1.80
自引率
16.70%
发文量
416
期刊介绍: Organ der Deutschen Gesellschaft für Pneumologie DGP Organ des Deutschen Zentralkomitees zur Bekämpfung der Tuberkulose DZK Organ des Bundesverbandes der Pneumologen BdP Fachärzte für Lungen- und Bronchialheilkunde, Pneumologen und Allergologen
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信